Difference between revisions of "Pandion Therapeutics"

From Wikitia
Jump to navigation Jump to search
(Created page with "{{Infobox company | name = Pandion Therapeutics | logo = | logo_size = | logo_alt = | logo_caption = | image = | image_size = | image_alt = | image_caption = | trade_n...")
 
(No difference)

Latest revision as of 05:48, 1 July 2020

Pandion Therapeutics
Private
IndustryBiotechnology
Founded2017; 3 years ago (2017)
HeadquartersWatertown, MA,
USA
Key people
  • Rahul Kakkar (CEO}
  • Jo Viney (Co-founder)
ProductsEngineered T cells
Websitepandiontx.com

Pandion Therapeutics is an early-stage biotech company developing engineered T cells for autoimmune diseases. It is currently developing PT101, is a combination of our interleukin-2 mutein effector module with a protein backbone designed to selectively expand regulatory T cells without activating proinflammatory cells. It was founded in 2017 in Watertown, MA.[1]

References

  1. Capital, Contributor Renaissance Capital Renaissance. "Autoimmune disease biotech Pandion Therapeutics files for a $75 million IPO". www.nasdaq.com. Retrieved 2020-06-29.

External links

This article "Pandion Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.